TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01602315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 as film-coated (FC) whole tablets
Description: Oral alpha-specific PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 as film-coated (FC) whole tablets
Description: Oral alpha-specific PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 as dispersible tablets (DT)
Description: New formulation of the oral alpha-specific PI3K inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Recombinant chimeric monoclonal antibody driven against EGFR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Recombinant chimeric monoclonal antibody driven against EGFR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Recombinant chimeric monoclonal antibody driven against EGFR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Recombinant chimeric monoclonal antibody driven against EGFR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Recombinant chimeric monoclonal antibody driven against EGFR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Recombinant chimeric monoclonal antibody driven against EGFR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Recombinant chimeric monoclonal antibody driven against EGFR
Study: NCT01805258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
Study: NCT01602315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 drink suspension
Description: Oral alpha-specific PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 drink suspension
Description: Oral alpha-specific PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 drink suspension
Description: Oral alpha-specific PI3K inhibitor
Study: NCT01267123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Description: The patient will be placed in the Trendelenburg position with a 15 degree angle of inclination

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard care
Description: The patient will be placed in the standard horizontal position
Study: NCT03890302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB704A
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB704A
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB704A
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB704A
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB704A
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
Study: NCT04020120

Intervention type: OTHER
Intervention: questionnaires
Description: answer questionnaires
Study: NCT04180982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose1 plus Febuxostat dose1
Description: Tablet,dose1,QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose1 plus Febuxostat dose2
Description: Tablet,dose1, dose2 QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose2 plus Febuxostat dose3
Description: Tablet,dose2, dose3 QD
Study: NCT03574220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV every 21 days over 6 months

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: 50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
Study: NCT02405455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerclage
Description: Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Description: The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
Study: NCT04522947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milkshake fMRI
Description: While in the MRI scanner, the participant is shown a cue indicating the impending delivery of either milkshake or tasteless solution, followed by a brief blank screen, then delivery of the sip, and then a swallow cue. This procedure is repeated throughout the task.
Study: NCT01855009

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MannaBears
Description: Subjects will be administered 4 MannaBears daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MannaBears
Description: Subjects will be administered 4 MannaBears daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MannaBears
Description: Subjects will be administered 4 MannaBears daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AlgaeCal Calcium
Description: Subjects will be administered 750 mg AlgaeCal Calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: Subjects will be administered 1000 mg calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Subjects will be administered 800 IU vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Subjects will be administered 800 IU vitamin D3
Study: NCT03156023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozibafusp Alfa
Description: Administered by subcutaneous injection once every 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once every 2 weeks.
Study: NCT03200522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prudent diet
Description: Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prudent diet
Description: Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western diet
Description: Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western diet
Description: Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.
Study: NCT06662916

Intervention type: BEHAVIORAL
Intervention: Microbiota-Diversity Enhancing Diet on children with Autism Spectrum Disorder
Description: Microbiota-Diversity Enhancing Diet on Children with ASD (MIND-DASE) suggested that increasing microbiota diversity through dietary interventions can have significant benefits on the neurodevelopmental outcomes of children with ASD
Study: NCT01805258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
Study: NCT03294434

Intervention type: OTHER
Intervention: Diffusion tensor Imaging (DTI)
Description: Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption. A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components. This can differentiate regions of pure tumour from invaded white matter.
Study: NCT02259621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 Therapy
Study: NCT02624817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: See Arm description.
Study: NCT03146507

Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasound
Description: ultrasound assessment of gestational age, amniotic fluid index, and fetal weight
Study: NCT02259621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Anti-PD-1 Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Anti-PD-1 Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Anti-PD-1 Therapy
Study: NCT03146507

Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasound
Description: ultrasound assessment of gestational age, amniotic fluid index, and fetal weight

Intervention type: RADIATION
Group type: OTHER
Intervention: Doppler ultrasound
Description: Umbilical artery and Middle cerebral artery Doppler blood flow assesment
Study: NCT05107986

Intervention type: PROCEDURE
Intervention: laparoscopic repair
Description: All patients of cohort underwent laparoscopic repair.
Study: NCT01083433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes related psychological counseling and education
Description: The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes related psychological counseling and education
Description: The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
Study: NCT04250324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BZ019
Description: A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
Study: NCT03981406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
Study: NCT03146507

Intervention type: RADIATION
Group type: OTHER
Intervention: Doppler ultrasound
Description: Umbilical artery and Middle cerebral artery Doppler blood flow assesment

Intervention type: RADIATION
Group type: OTHER
Intervention: Fetal echocardiography
Description: The cardiac output (ratio between right side cardiac outputs to left side cardiac output) was calculated
Study: NCT03981406

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Control group will receive standard of care treatment for IPF.
Study: NCT03554122

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shotblocker
Description: Patients spinal injections were performed with Shotblocker placed onto injection site
Study: NCT03146507

Intervention type: RADIATION
Group type: OTHER
Intervention: Fetal echocardiography
Description: The cardiac output (ratio between right side cardiac outputs to left side cardiac output) was calculated
Study: NCT01906034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise with supervision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based without supervision
Study: NCT03338673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
Study: NCT00538707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-minute Bondet test
Description: 2-minute Bondet test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-minute Bondet test
Description: 2-minute Bondet test
Study: NCT02006355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study: NCT01932801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-NTX

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HRC

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HRC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRC
Study: NCT04181294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual practice
Description: Baseline practice of ICU communication and care planning
Study: NCT03450317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 80mg
Description: No treatment
Study: NCT01139775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously as a continuous 10-minute infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered intravenously as a continuous 10-minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously as a continuous 10-minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously as a continuous 1-hour infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously as a continuous 1-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously as a continuous 1-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618
Description: Administered intravenously as a continuous 1-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618
Description: Administered intravenously as a continuous 1-hour infusion
Study: NCT00039559

Intervention type: OTHER
Group type: OTHER
Intervention: Early detection
Description: CA125 is measured in blood and the longitudinal results interpreted with a statistical algorithm to determine if there has been a significant increase from baseline.
Study: NCT04655560

Intervention type: OTHER
Intervention: no intervention
Description: qualitative study
Study: NCT04561934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver diamine fluoride
Description: Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin modified glassionomer cement
Description: resin modified glassionomer cement
Study: NCT04057573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT00803530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATO + Ascorbic acid
Description: ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution.
Study: NCT02955394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: 500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
Study: NCT01281631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP001
Description: Low dose of NP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP001
Description: High dose of NP001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study: NCT01450150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: 20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
Study: NCT01819701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LC-1000
Description: L-carnitine 1000 mg /d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LC-2000
Description: L-carnitine: 2000 mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Q10-150
Description: Coenzyme Q10: 150 mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Q10-300
Description: Coenzyme Q10: 300 mg/d

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01270607

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Treatment given twice per week for 4 weeks
Study: NCT03403712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosnetupitant/ palonosetron
Description: intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: netupitant/palonosetron
Description: oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Oral dexamethasone (12 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral dexamethasone (12 mg)
Study: NCT04567160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. Marsh pharmacokinetic model will be used to set the initial target predicted effect-site concentration of propofol at 3.0 mcg/ml in flash mode. Simultaneously, target-controlled infusion of remifentanil will be started to reach an initial target predicted effect-site concentration of 3 ng/mL using the Minto pharmacokinetic model.~After tracheal intubation, TCI of remifentanil is paused.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. After tracheal intubation, TCI of remifentanil is paused.